Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELE | P16581 | 1/20 | 0.51 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3980685 | 0.82 | SELE (0.51) | SELEVCAM1HDAC3HDAC1HDAC6 | |
| SCHEMBL6495650 | 0.79 | EGFR (0.39) | SELEVCAM1EGFRPIP4K2A | |
| SCHEMBL30408920 | 0.72 | SELE (0.56) | SELEVCAM1EGFRHDAC3HDAC1 | |
| SCHEMBL6484704 | 0.72 | SELE (0.56) | SELEVCAM1EGFRHDAC3HDAC1 | |
| SCHEMBL654782 | 0.72 | SELE (0.56) | SELEVCAM1EGFRHDAC3HDAC1 | |
| SCHEMBL1368716 | 0.72 | SELE (0.61) | SELEVCAM1HDAC3HDAC1HDAC6 | |
| SCHEMBL6829304 | 0.71 | EGFR (0.48) | SELEVCAM1EGFRHDAC3HDAC1 | |
| SCHEMBL2878910 | 0.71 | NPC1 (0.43) | SELEVCAM1PDE4APDE4BPDE4C | |
| SCHEMBL1163972 | 0.69 | EGFR (0.64) | EGFRHDAC3HDAC1HDAC6PIP4K2A | |
| SCHEMBL10325118 | 0.68 | SELE (0.51) | SELEVCAM1EGFRHDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009845-A1 | Thienopyrimidine compounds as protein tyrosine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009845-A1 | Thienopyrimidine compounds as protein tyrosine kinase inhibitors | ERBB2, ERBB4, ERBB3 | SELE 4102/4885VCAM1 4288/4885EGFR 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.